Cortey A, Brossard Y
Centre National de Référence en Hémobiologie Périnatale (CNRHP), Hôpital Saint-Antoine, 184, rue du Faubourg-Saint-Antoine, 75012 Paris.
J Gynecol Obstet Biol Reprod (Paris). 2006 Feb;35(1 Suppl):1S112-1S118.
Anti-D prophylaxis should be proposed to all RhD negative non-sensitized pregnant women, after delivering an information concerning both Rhesus disease and anti-D immunoglobulins. This information must be delivered as a written document and the patient's oral consent is required before administration of the anti-D immunoglobulins. Anti-D immunoglobulins currently used in France for prophylaxis are extracted from plasma of hyperimmunized paid donors. Even if all the conditions of viral safety are fulfilled in the preparation of anti-D immunoglobulins, they remain blood derived products. As such, prescription of anti-D immunoglobulins should follow legal rules concerning tracability and information. Refusal of rhesus prophylaxis can occur but should be transcribed and motivated in the patient's chart. Administration of anti-D immunoglobulins is usually well tolerated. Reactions to hemolysis of fetal Rhesus positive red cells can occur but remain rare and linked to important foeto-maternal hemorrhage. They can be easily prevented or treated by anti-inflammatory drugs. Patients can be vaccinated against rubella in the post-partum period even though they will receive a concomitant prophylaxis with Rh immunoglobulin. Persistence of passive anti-D in maternal circulation after injection lasts several weeks or months and could have various consequences. In the mother: it can interfere with diagnosis of active anti-D immunization. In most cases, it may be possible to differentiate passive and immune anti-D. When reliable information concerning date and dosage of antenatal anti-D prophylaxis are available. In the newborn: anti-D immunoglobulins can pass through the placenta and enter the fetal circulation, coat the D positive fetal red cells and give positive DAT. Positive DAT is reported in 5 to 15% of the newborns following rhesus prophylaxis in the third trimester but with no report of anemia or jaundice. In absence of ABO incompatibility, no additional investigation is needed in these newborns.
对于所有RhD阴性且未致敏的孕妇,在提供有关恒河猴病和抗D免疫球蛋白的信息后,应建议进行抗D预防。此信息必须以书面文件形式提供,在给予抗D免疫球蛋白之前需要患者的口头同意。目前法国用于预防的抗D免疫球蛋白是从超免疫有偿献血者的血浆中提取的。即使在抗D免疫球蛋白的制备过程中满足了所有病毒安全条件,它们仍然是血液制品。因此,抗D免疫球蛋白的处方应遵循有关可追溯性和信息的法律规定。可能会出现拒绝进行恒河猴预防的情况,但应在患者病历中记录并说明理由。抗D免疫球蛋白的给药通常耐受性良好。对胎儿Rh阳性红细胞溶血的反应可能会发生,但仍然很少见,并且与严重的母婴出血有关。它们可以很容易地通过抗炎药物预防或治疗。产后患者即使同时接受Rh免疫球蛋白预防,也可以接种风疹疫苗。注射后母体循环中被动抗D的持续存在会持续数周或数月,并可能产生各种后果。在母亲方面:它可能会干扰主动抗D免疫的诊断。在大多数情况下,当可获得有关产前抗D预防的日期和剂量的可靠信息时,有可能区分被动和免疫抗D。在新生儿方面:抗D免疫球蛋白可以穿过胎盘进入胎儿循环,覆盖D阳性胎儿红细胞并产生阳性直接抗人球蛋白试验(DAT)。在妊娠晚期进行恒河猴预防后,5%至15%的新生儿会出现阳性DAT,但没有贫血或黄疸的报告。在不存在ABO血型不合的情况下,这些新生儿无需进行额外检查。